Vidarabine is used to treat hepatitis B

Vidarabine has a strong antiviral effect. It has been demonstrated that the main role of Vidarabine is to inhibit the viral DNA polymerase by acting more than the human cell DNA polymerase. Therefore, it can preferentially inhibit viral DNA synthesis at therapeutic concentrations, and is relatively less toxic to human cells. Vidarabine inhibits the level of hepatitis B virus deoxyribonucleic acid polymerase, which is faster and more obvious than interferon; however, the inhibition lasts for a short time and is easy to rebound after stopping the drug, so it is second to interferon in the continuous replication against hepatitis B virus; Vidarabine has low water solubility, and it must be diluted to 0.7mg/mL in clinical application for intravenous drip. After 30 minutes of intravenous injection, the blood concentration peaks, but after stopping the drip, the plasma drug concentration is very fast. The drop is not detected after 15-20 minutes. After switching to a monophosphate compound, the solubility is 100-400 times that of adenosine, which can be used for intramuscular injection and intravenous infusion, after intramuscular injection. It took 3 hours for the blood concentration to peak.
Vidarabine usage: 10-15mg/kg body weight per day, diluted in 1000ml 5%-10% glucose solution, slow intravenous infusion within 12 hours, course of treatment 10-30 days, also reduced the dose to 5-10mg/kg body weight per day, think The effect is the same.
Vidarabine monophosphate compound 5-10mg/kg body weight per day, divided into 2 intramuscular injections, the same course of treatment, can also be extended for 8 weeks. After the e antigen of the hepatitis B virus is negatively transfected, the e-antibody-positive seroconversion rate is between 5% and 55%. High-dose applications can have adverse reactions such as fever, nausea, vomiting, thrombocytopenia, and myopathy syndrome of lower extremity muscle rigidity. In 2007, the United States reported that Vidarabione monophosphate compound has a strong antiviral effect and can transiently reduce the serum level of hepatitis B virus. However, after the treatment of hepatitis B with this drug for more than one month, high neurotoxicity may occur. Therefore, it is not advisable to apply it casually.